首页 > 最新文献

Journal of cancer & allied specialties最新文献

英文 中文
Reduction in Average Length-of-Stay in Emergency Department of a Low-Income Country's Cancer Hospital. 减少低收入国家癌症医院急诊科的平均住院时间。
Pub Date : 2024-01-22 eCollection Date: 2024-01-01 DOI: 10.37029/jcas.v10i1.537
Qurratulain Shakoor, Haroon Hafeez, Atif Saleem, Zubair Shabbir Khanzada, Hira Safir, Zainab Ajmal, Kashif Sajjad

Introduction: Prolonged length of stay (LOS) in emergency departments (ED) is a widespread problem in every hospital around the globe. Multiple factors cause it and can have a negative impact on the quality of care provided to the patients and the patient satisfaction rates. This project aimed to ensure that the average LOS of patients in a tertiary care cancer hospital stays below 3 hours.

Materials and methods: The Six Sigma DMAIC (Define, Measure, Analyze, Improve, Control) approach was followed.

Results: The average LOS was 166 minutes before implementing interventions. The two primary reasons for the increased length of stay were delays secondary to physician assessment and diagnostic lab reports. Strategies were defined to control these factors, which helped reduce the average length of stay to 142 minutes, a 30% reduction.

Conclusion: A process improvement model similar to this project is recommended to enhance the quality of hospital services. It will provide valuable insights into the process flow and assist in gathering precise data on the various steps involved. The data collected can then be analyzed to identify potential causes and make informed decisions that can significantly improve hospital processes.

导言:急诊科(ED)的住院时间(LOS)过长是全球每家医院都普遍存在的问题。造成这一问题的原因是多方面的,而且会对为患者提供的医疗服务质量和患者满意度产生负面影响。本项目旨在确保一家三级癌症医院患者的平均候诊时间保持在 3 小时以下:采用六西格玛 DMAIC(定义、测量、分析、改进、控制)方法:结果:在实施干预措施之前,平均住院时间为 166 分钟。住院时间延长的两个主要原因是医生评估和实验室诊断报告造成的延误。我们制定了控制这些因素的策略,从而将平均住院时间缩短至 142 分钟,缩短了 30%:建议采用与本项目类似的流程改进模式来提高医院服务质量。它将为流程提供有价值的见解,并有助于收集有关各个步骤的精确数据。然后可以对收集到的数据进行分析,找出潜在的原因,并做出明智的决定,从而大大改善医院的流程。
{"title":"Reduction in Average Length-of-Stay in Emergency Department of a Low-Income Country's Cancer Hospital.","authors":"Qurratulain Shakoor, Haroon Hafeez, Atif Saleem, Zubair Shabbir Khanzada, Hira Safir, Zainab Ajmal, Kashif Sajjad","doi":"10.37029/jcas.v10i1.537","DOIUrl":"10.37029/jcas.v10i1.537","url":null,"abstract":"<p><strong>Introduction: </strong>Prolonged length of stay (LOS) in emergency departments (ED) is a widespread problem in every hospital around the globe. Multiple factors cause it and can have a negative impact on the quality of care provided to the patients and the patient satisfaction rates. This project aimed to ensure that the average LOS of patients in a tertiary care cancer hospital stays below 3 hours.</p><p><strong>Materials and methods: </strong>The Six Sigma DMAIC (Define, Measure, Analyze, Improve, Control) approach was followed.</p><p><strong>Results: </strong>The average LOS was 166 minutes before implementing interventions. The two primary reasons for the increased length of stay were delays secondary to physician assessment and diagnostic lab reports. Strategies were defined to control these factors, which helped reduce the average length of stay to 142 minutes, a 30% reduction.</p><p><strong>Conclusion: </strong>A process improvement model similar to this project is recommended to enhance the quality of hospital services. It will provide valuable insights into the process flow and assist in gathering precise data on the various steps involved. The data collected can then be analyzed to identify potential causes and make informed decisions that can significantly improve hospital processes.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"10 1","pages":"537"},"PeriodicalIF":0.0,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10793720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139520119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival Analysis and Correlates with Molecular Epidemiology: 10-Year Retrospective Series of High-Grade Glioma in Pakistan. 生存期分析及与分子流行病学的相关性:巴基斯坦高级别胶质瘤 10 年回顾性系列研究。
Pub Date : 2024-01-22 eCollection Date: 2024-01-01 DOI: 10.37029/jcas.v10i1.565
Mashal Shah, Saad Bin Anis, Irfan Yusuf, Mohammad Hamza Bajwa

Introduction: High-grade gliomas are malignant, recurring primary central nervous system (CNS) tumors requiring extensive postoperative chemotherapy and radiation treatment. Isocitrate dehydrogenase (IDH), 1p19q, and ATRX mutations significantly influence survival and response to chemotherapy, as seen in many extensive studies from the Global North. This study aims to report data from the local region regarding progression-free survival and overall survival in light of molecular characteristics.

Materials and methods: A 10-year retrospective series was conducted at the Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan, with 285 patients presenting from 2008 to 2018. Prospective follow-up data was collected, and complete molecular profiles were available for patients presenting from 2010 onwards. Survival analysis was conducted through the Kaplan-Meier method, with log-rank reported.

Results: 70.53% (201) of patients were male, with a mean age at diagnosis of 43.33 ± 15.1 years. 265 patients within the cohort completed postoperative radiotherapy, while 141 patients underwent chemotherapy (procarbazine, lomustine, and vincristine, or temozolomide). Mean survival, in months, within the cohort was as follows: glioblastoma (14.1), anaplastic astrocytoma (27.5), and anaplastic oligodendroglioma (39.8). Survival curves showed a lower survival for IDH wild-type (P < 0.0001), ATRX mutated (P = 0.029), and 1p19q non-deleted (P = 0.008) tumors from Pakistan.

Discussion: Our findings quantified long-term survival outcomes for high-grade glioma from Pakistan, analyzing the various treatment patterns. Of particular importance, molecular sub-classification significantly predicted survival outcomes for IDH, ATRX, and 1p19 co-deletion mutations. Expanding brain tumor epidemiology will benefit assessing the efficacy of regional oncological centers and establishing standards of care.

简介高级别胶质瘤是一种恶性、复发性原发性中枢神经系统(CNS)肿瘤,需要大量的术后化疗和放疗。异柠檬酸脱氢酶(IDH)、1p19q 和 ATRX 基因突变对患者的生存和化疗反应有显著影响,这一点在全球北方地区的许多广泛研究中都有体现。本研究旨在根据分子特征报告当地地区的无进展生存期和总生存期数据:巴基斯坦拉合尔的肖卡特-卡努姆纪念癌症医院和研究中心开展了一项为期 10 年的回顾性系列研究,共有 285 名患者在 2008 年至 2018 年期间就诊。收集了前瞻性随访数据,并为2010年以后的患者提供了完整的分子图谱。通过卡普兰-梅耶法进行生存分析,并报告对数秩:70.53%的患者(201人)为男性,诊断时的平均年龄为(43.33 ± 15.1)岁。队列中有 265 名患者完成了术后放疗,141 名患者接受了化疗(丙卡巴嗪、洛莫司汀和长春新碱或替莫唑胺)。队列中以月为单位的平均生存期如下:胶质母细胞瘤(14.1 个月)、无细胞星形细胞瘤(27.5 个月)和无细胞少突胶质细胞瘤(39.8 个月)。生存曲线显示,来自巴基斯坦的IDH野生型肿瘤(P < 0.0001)、ATRX突变肿瘤(P = 0.029)和1p19q未缺失肿瘤(P = 0.008)的生存率较低:我们的研究结果量化了巴基斯坦高级别胶质瘤患者的长期生存结果,分析了各种治疗模式。尤其重要的是,分子亚分类可显著预测IDH、ATRX和1p19共缺失突变的生存结果。扩大脑肿瘤流行病学将有利于评估地区肿瘤中心的疗效和建立治疗标准。
{"title":"Survival Analysis and Correlates with Molecular Epidemiology: 10-Year Retrospective Series of High-Grade Glioma in Pakistan.","authors":"Mashal Shah, Saad Bin Anis, Irfan Yusuf, Mohammad Hamza Bajwa","doi":"10.37029/jcas.v10i1.565","DOIUrl":"10.37029/jcas.v10i1.565","url":null,"abstract":"<p><strong>Introduction: </strong>High-grade gliomas are malignant, recurring primary central nervous system (CNS) tumors requiring extensive postoperative chemotherapy and radiation treatment. Isocitrate dehydrogenase (IDH), 1p19q, and ATRX mutations significantly influence survival and response to chemotherapy, as seen in many extensive studies from the Global North. This study aims to report data from the local region regarding progression-free survival and overall survival in light of molecular characteristics.</p><p><strong>Materials and methods: </strong>A 10-year retrospective series was conducted at the Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan, with 285 patients presenting from 2008 to 2018. Prospective follow-up data was collected, and complete molecular profiles were available for patients presenting from 2010 onwards. Survival analysis was conducted through the Kaplan-Meier method, with log-rank reported.</p><p><strong>Results: </strong>70.53% (201) of patients were male, with a mean age at diagnosis of 43.33 ± 15.1 years. 265 patients within the cohort completed postoperative radiotherapy, while 141 patients underwent chemotherapy (procarbazine, lomustine, and vincristine, or temozolomide). Mean survival, in months, within the cohort was as follows: glioblastoma (14.1), anaplastic astrocytoma (27.5), and anaplastic oligodendroglioma (39.8). Survival curves showed a lower survival for IDH wild-type (<i>P</i> < 0.0001), ATRX mutated (<i>P</i> = 0.029), and 1p19q non-deleted (<i>P</i> = 0.008) tumors from Pakistan.</p><p><strong>Discussion: </strong>Our findings quantified long-term survival outcomes for high-grade glioma from Pakistan, analyzing the various treatment patterns. Of particular importance, molecular sub-classification significantly predicted survival outcomes for IDH, ATRX, and 1p19 co-deletion mutations. Expanding brain tumor epidemiology will benefit assessing the efficacy of regional oncological centers and establishing standards of care.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"10 1","pages":"565"},"PeriodicalIF":0.0,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10793716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139520250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric Ewing Sarcoma of Kidney: A Case Series and Review of Literature. 小儿肾脏尤文肉瘤:病例系列和文献综述
Pub Date : 2024-01-22 eCollection Date: 2024-01-01 DOI: 10.37029/jcas.v10i1.563
Areej Salim, Sajid Ali, Tariq Latif

Introduction: Renal Ewing sarcoma is an aggressive and rare malignancy affecting children and adolescents. Limited data on its management contribute to uncertainties in treatment.

Case description: We present two pediatric cases of renal Ewing sarcoma. Both cases emphasize the significance of accurate diagnosis, multimodal treatment, and long-term follow-up in achieving favorable outcomes. Accurate diagnosis of renal Ewing sarcoma is crucial for effective management. Multimodal treatment involving neoadjuvant chemotherapy, surgical resection and staging with lymph node sampling, and chemotherapy continuation has shown promising results in our cases. Long-term follow-up is essential for monitoring disease progression and ensuring optimal outcomes.

Practical implications: There is limited data published about these renal tumors, especially in the pediatric population, and most studies lack long-term follow-up, with uncertain management due to limited data. This data will add to the newer, multimodal approach and form the basis for future meta-analysis to help formulate guidelines for upcoming international meetings. Continued research efforts are necessary to optimize strategies and improve the prognosis for pediatric patients with renal Ewing sarcoma.

简介肾尤文肉瘤是一种侵袭性的罕见恶性肿瘤,多发于儿童和青少年。有关其治疗的数据有限,导致治疗的不确定性:我们介绍了两例肾尤文肉瘤儿科病例。两例病例都强调了准确诊断、多模式治疗和长期随访对取得良好疗效的重要意义。肾尤文肉瘤的准确诊断对于有效治疗至关重要。在我们的病例中,包括新辅助化疗、手术切除和淋巴结取样分期以及继续化疗在内的多模式治疗取得了良好的效果。长期随访对于监测疾病进展和确保最佳治疗效果至关重要:有关这些肾肿瘤的数据有限,尤其是在儿童群体中,而且大多数研究缺乏长期随访,由于数据有限,治疗方法也不确定。这些数据将为较新的多模式方法提供补充,并为未来的荟萃分析奠定基础,有助于为即将召开的国际会议制定指导方针。有必要继续开展研究工作,以优化策略,改善肾性尤文肉瘤儿科患者的预后。
{"title":"Pediatric Ewing Sarcoma of Kidney: A Case Series and Review of Literature.","authors":"Areej Salim, Sajid Ali, Tariq Latif","doi":"10.37029/jcas.v10i1.563","DOIUrl":"10.37029/jcas.v10i1.563","url":null,"abstract":"<p><strong>Introduction: </strong>Renal Ewing sarcoma is an aggressive and rare malignancy affecting children and adolescents. Limited data on its management contribute to uncertainties in treatment.</p><p><strong>Case description: </strong>We present two pediatric cases of renal Ewing sarcoma. Both cases emphasize the significance of accurate diagnosis, multimodal treatment, and long-term follow-up in achieving favorable outcomes. Accurate diagnosis of renal Ewing sarcoma is crucial for effective management. Multimodal treatment involving neoadjuvant chemotherapy, surgical resection and staging with lymph node sampling, and chemotherapy continuation has shown promising results in our cases. Long-term follow-up is essential for monitoring disease progression and ensuring optimal outcomes.</p><p><strong>Practical implications: </strong>There is limited data published about these renal tumors, especially in the pediatric population, and most studies lack long-term follow-up, with uncertain management due to limited data. This data will add to the newer, multimodal approach and form the basis for future meta-analysis to help formulate guidelines for upcoming international meetings. Continued research efforts are necessary to optimize strategies and improve the prognosis for pediatric patients with renal Ewing sarcoma.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"10 1","pages":"563"},"PeriodicalIF":0.0,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10793718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139520079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of SSO-ASTRO Margin Guidelines on Re-excision Rate in Breast-conserving Surgery: A Single-center Experience. SSO-ASTRO边缘指南对保乳房手术中再次切除率的影响:单中心经验
Pub Date : 2024-01-22 eCollection Date: 2024-01-01 DOI: 10.37029/jcas.v10i1.559
Namra Urooj, Muhammad Abubakar, Kashif Asghar, Muhammad Hassan, Awais Amjad Malik, Bushra Rehman, Bakra Sajjad, Nifasat Farooqi, Zulqarnain Chaudhry, Asad Parvaiz, Amina Khan

Introduction: Breast-conserving surgery (BCS) has been historically linked with a high rate of re-excision. To address this issue, the Society of Surgical Oncology (SSO) and the American Society for Radiation Oncology (ASTRO) developed consensus guidelines in 2014 to standardize practices and improve clinical outcomes for BCS patients. In our tertiary cancer care hospital, we assessed the impact of these guidelines on the re-excision rate following BCS.

Materials and methods: We conducted a retrospective study on breast cancer patients who underwent BCS at the Shaukat Khanum Memorial Cancer Hospital and Research Centre in Lahore, Pakistan. The study compared the re-excision rate before the implementation of the SSO-ASTRO consensus guidelines (November 2015-July 2017) and after the implementation (January 2018-August 2019). Margins were considered positive if "ink on tumor" was present and negative if "no ink on tumor" was present. Fisher's exact test or Chi-square test was used to compare the re-excision rates between the pre- and post-guideline periods.

Results: A total of 919 patients were identified, with 533 from the pre-guideline period and 386 from the post-guideline period. Of the 919 patients, 31 with ductal carcinoma in situ (DCIS) were excluded from the re-excision analysis because the guidelines were not implemented on the DCIS. Furthermore, the overall rate of re-excision in our data was 4.3%. The re-excision rate decreased from 71.1% to 28.9% (P ≤ 0.05) following the adoption of the guidelines. We observed a statistically significant decrease in the re-excision rate after implementing the SSO-ASTRO guidelines.

Conclusion: Implementation of the SSO-ASTRO margin guidelines led to a notable decrease in the overall re-excision rate in our data set. These findings suggest that continued adherence to the guidelines may lead to a further reduction in the re-excision rate in the future.

简介保乳手术(BCS)历来与高重切率有关。为解决这一问题,肿瘤外科学会(SSO)和美国放射肿瘤学会(ASTRO)于 2014 年制定了共识指南,以规范操作并改善 BCS 患者的临床疗效。在我们的三级癌症治疗医院,我们评估了这些指南对 BCS 后再次切除率的影响:我们对在巴基斯坦拉合尔肖卡特-卡努姆纪念癌症医院和研究中心接受 BCS 的乳腺癌患者进行了一项回顾性研究。研究比较了SSO-ASTRO共识指南实施前(2015年11月-2017年7月)和实施后(2018年1月-2019年8月)的再切除率。如果 "肿瘤上有墨迹",则边缘被视为阳性;如果 "肿瘤上没有墨迹",则边缘被视为阴性。采用费雪精确检验或卡方检验比较指南实施前后的再切除率:结果:共发现 919 例患者,其中 533 例来自指南发布前,386 例来自指南发布后。在这 919 名患者中,有 31 名患有导管原位癌(DCIS)的患者被排除在再次切除分析之外,因为指南并未针对 DCIS 实施。此外,在我们的数据中,再次切除的总体比例为 4.3%。采用该指南后,再次切除率从 71.1% 降至 28.9%(P ≤ 0.05)。我们观察到,在实施 SSO-ASTRO 指南后,再次切除率在统计学上有了明显下降:结论:在我们的数据集中,SSO-ASTRO 边界指南的实施显著降低了总体再切除率。这些研究结果表明,今后继续遵循该指南可能会进一步降低再切除率。
{"title":"Impact of SSO-ASTRO Margin Guidelines on Re-excision Rate in Breast-conserving Surgery: A Single-center Experience.","authors":"Namra Urooj, Muhammad Abubakar, Kashif Asghar, Muhammad Hassan, Awais Amjad Malik, Bushra Rehman, Bakra Sajjad, Nifasat Farooqi, Zulqarnain Chaudhry, Asad Parvaiz, Amina Khan","doi":"10.37029/jcas.v10i1.559","DOIUrl":"10.37029/jcas.v10i1.559","url":null,"abstract":"<p><strong>Introduction: </strong>Breast-conserving surgery (BCS) has been historically linked with a high rate of re-excision. To address this issue, the Society of Surgical Oncology (SSO) and the American Society for Radiation Oncology (ASTRO) developed consensus guidelines in 2014 to standardize practices and improve clinical outcomes for BCS patients. In our tertiary cancer care hospital, we assessed the impact of these guidelines on the re-excision rate following BCS.</p><p><strong>Materials and methods: </strong>We conducted a retrospective study on breast cancer patients who underwent BCS at the Shaukat Khanum Memorial Cancer Hospital and Research Centre in Lahore, Pakistan. The study compared the re-excision rate before the implementation of the SSO-ASTRO consensus guidelines (November 2015-July 2017) and after the implementation (January 2018-August 2019). Margins were considered positive if \"ink on tumor\" was present and negative if \"no ink on tumor\" was present. Fisher's exact test or Chi-square test was used to compare the re-excision rates between the pre- and post-guideline periods.</p><p><strong>Results: </strong>A total of 919 patients were identified, with 533 from the pre-guideline period and 386 from the post-guideline period. Of the 919 patients, 31 with ductal carcinoma <i>in situ</i> (DCIS) were excluded from the re-excision analysis because the guidelines were not implemented on the DCIS. Furthermore, the overall rate of re-excision in our data was 4.3%. The re-excision rate decreased from 71.1% to 28.9% (<i>P</i> ≤ 0.05) following the adoption of the guidelines. We observed a statistically significant decrease in the re-excision rate after implementing the SSO-ASTRO guidelines.</p><p><strong>Conclusion: </strong>Implementation of the SSO-ASTRO margin guidelines led to a notable decrease in the overall re-excision rate in our data set. These findings suggest that continued adherence to the guidelines may lead to a further reduction in the re-excision rate in the future.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"10 1","pages":"559"},"PeriodicalIF":0.0,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10793721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139520056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emergency Angioembolization for Life-Threatening Hemorrhage in Wilms Tumor. 紧急血管栓塞术治疗威尔姆斯肿瘤危及生命的出血。
Pub Date : 2024-01-22 eCollection Date: 2024-01-01 DOI: 10.37029/jcas.v10i1.603
Areej Salim, Sajid Ali, Muhammad Ali Sheikh, Tariq Latif, Islah Ud Din

Introduction: Renal artery embolization has been used in a palliative fashion for symptomatic relief of hematuria or flank pain in unresectable renal cell carcinoma in adults. There is limited data on the use of embolization for actively bleeding and unresectable tumors in the oncological pediatric population.

Case description: A previously healthy 5-year-old boy with no significant past medical or surgical history presented to the clinic with gradually worsening abdominal distension associated with occasional abdominal pain, gross hematuria, and lethargy for four months. Diagnostic investigations showed an 18-cm left-sided metastatic (pulmonary) renal tumor (Wilms), which was deemed unresectable on imaging. Treatment was planned according to the SIOP-RTSG protocol. However, he became hemodynamically and vitally unstable with acute, sudden distension of the abdomen on the left side after the first cycle of chemotherapy. Imaging showed active bleeding from an inferior branch of the left renal artery. Selective angioembolization was done, and chemotherapy was reinitiated with a patent left main renal artery. Following the fourth cycle of chemotherapy, he developed hemodynamic instability and abdominal pain; imaging revealed the resolution of pulmonary nodules and bleeding from the left renal artery (main); this was again embolized, and the patient was stabilized. The patient was operated on after optimization, and a complete resection of the mass was done with negative margins. On six months follow-up, he is well.

Practical implications: To the best of our knowledge, this is the first case where angioembolization has been done in conjunction with neoadjuvant chemotherapy to downsize a Wilms tumor to achieve favorable outcomes. Continued research efforts are necessary to optimize strategies and improve the prognosis for pediatric patients, and this case is one of the prime examples.

导言:肾动脉栓塞术已被用于缓解成人不可切除肾细胞癌患者的血尿或侧腹疼痛症状。在儿科肿瘤患者中,使用栓塞治疗活动性出血和不可切除肿瘤的数据有限:一名既往无明显内科或外科病史的 5 岁健康男孩因腹胀逐渐加重并伴有偶发性腹痛、毛细血尿和嗜睡 4 个月而就诊。诊断检查显示他患有 18 厘米的左侧转移性(肺)肾肿瘤(Wilms),影像学检查认为无法切除。根据 SIOP-RTSG 方案计划进行治疗。然而,第一个化疗周期结束后,他的左侧腹部突然出现急性腹胀,血流动力学和生命体征变得不稳定。影像学检查显示,左肾动脉下支有活动性出血。患者接受了选择性血管栓塞术,并在左肾主动脉通畅的情况下重新开始化疗。第四个化疗周期后,他出现了血流动力学不稳定和腹痛;造影显示肺结节消退,左肾动脉(主干)出血;再次进行了栓塞,患者病情稳定。经过优化后对患者进行了手术,在阴性边缘下完全切除了肿块。随访 6 个月后,患者情况良好:据我们所知,这是首例血管栓塞术与新辅助化疗相结合缩小 Wilms 肿瘤并取得良好疗效的病例。有必要继续开展研究工作,以优化策略并改善儿童患者的预后,本病例就是最好的例子之一。
{"title":"Emergency Angioembolization for Life-Threatening Hemorrhage in Wilms Tumor.","authors":"Areej Salim, Sajid Ali, Muhammad Ali Sheikh, Tariq Latif, Islah Ud Din","doi":"10.37029/jcas.v10i1.603","DOIUrl":"10.37029/jcas.v10i1.603","url":null,"abstract":"<p><strong>Introduction: </strong>Renal artery embolization has been used in a palliative fashion for symptomatic relief of hematuria or flank pain in unresectable renal cell carcinoma in adults. There is limited data on the use of embolization for actively bleeding and unresectable tumors in the oncological pediatric population.</p><p><strong>Case description: </strong>A previously healthy 5-year-old boy with no significant past medical or surgical history presented to the clinic with gradually worsening abdominal distension associated with occasional abdominal pain, gross hematuria, and lethargy for four months. Diagnostic investigations showed an 18-cm left-sided metastatic (pulmonary) renal tumor (Wilms), which was deemed unresectable on imaging. Treatment was planned according to the SIOP-RTSG protocol. However, he became hemodynamically and vitally unstable with acute, sudden distension of the abdomen on the left side after the first cycle of chemotherapy. Imaging showed active bleeding from an inferior branch of the left renal artery. Selective angioembolization was done, and chemotherapy was reinitiated with a patent left main renal artery. Following the fourth cycle of chemotherapy, he developed hemodynamic instability and abdominal pain; imaging revealed the resolution of pulmonary nodules and bleeding from the left renal artery (main); this was again embolized, and the patient was stabilized. The patient was operated on after optimization, and a complete resection of the mass was done with negative margins. On six months follow-up, he is well.</p><p><strong>Practical implications: </strong>To the best of our knowledge, this is the first case where angioembolization has been done in conjunction with neoadjuvant chemotherapy to downsize a Wilms tumor to achieve favorable outcomes. Continued research efforts are necessary to optimize strategies and improve the prognosis for pediatric patients, and this case is one of the prime examples.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"10 1","pages":"603"},"PeriodicalIF":0.0,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10793714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139522419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic Diseases and Gastrointestinal Cancer Risk. 系统性疾病和胃肠道癌症风险。
Pub Date : 2023-01-01 DOI: 10.37029/jcas.v9i2.473
Naila Malkani, Muhammad Usman Rashid

Importance: Gastrointestinal (GI) cancers are the second leading cause of cancer-related deaths worldwide.

Observations: The global challenges GI cancers pose are high, especially in middle- and low-income countries. Patients with these cancers present with symptoms of poor appetite, weight loss, heartburn, abdominal pain, fatigue and anaemia. Several risk factors contribute to GI cancers, including age, gender, obesity, pathogenic infections, smoking cigarettes, alcohol consumption and dietary habits. Most of these cancers are sporadic. However, some patients are at high risk due to a family history of GI cancers. Systemic diseases affect multiple organs, and their chronic occurrence elicits inflammatory responses at various sites. These diseases also contribute to GI cancers.

Conclusion and relevance: In this review, we discuss that untreated systemic diseases, including diabetes, hepatitis, acquired immune deficiency syndrome, ulcers and hypertension, can potentially lead to GI cancers if they remain untreated for a longer period. Systemic diseases initiate oxidative stress, inflammatory pathways and genetic manipulations, which altogether confer risks to GI cancers. Here, we describe the association between systemic diseases and their underlying mechanisms leading to GI cancers.

重要性:胃肠道(GI)癌症是全球癌症相关死亡的第二大原因。观察结果:胃肠道癌症带来的全球挑战很高,特别是在中低收入国家。这些癌症的患者表现为食欲不振、体重减轻、胃灼热、腹痛、疲劳和贫血。有几个风险因素会导致胃肠道癌症,包括年龄、性别、肥胖、致病性感染、吸烟、饮酒和饮食习惯。这些癌症大多是散发性的。然而,由于有胃肠道癌症的家族史,一些患者的风险很高。全身性疾病影响多个器官,其慢性发生可引起不同部位的炎症反应。这些疾病也会导致胃肠道癌症。结论和相关性:在这篇综述中,我们讨论了未经治疗的全身性疾病,包括糖尿病、肝炎、获得性免疫缺陷综合征、溃疡和高血压,如果长期未经治疗,可能会导致胃肠道癌症。全身性疾病引发氧化应激、炎症途径和基因操纵,这些因素共同导致消化道癌症的风险。在这里,我们描述了全身性疾病及其导致胃肠道癌症的潜在机制之间的关联。
{"title":"Systemic Diseases and Gastrointestinal Cancer Risk.","authors":"Naila Malkani,&nbsp;Muhammad Usman Rashid","doi":"10.37029/jcas.v9i2.473","DOIUrl":"https://doi.org/10.37029/jcas.v9i2.473","url":null,"abstract":"<p><strong>Importance: </strong>Gastrointestinal (GI) cancers are the second leading cause of cancer-related deaths worldwide.</p><p><strong>Observations: </strong>The global challenges GI cancers pose are high, especially in middle- and low-income countries. Patients with these cancers present with symptoms of poor appetite, weight loss, heartburn, abdominal pain, fatigue and anaemia. Several risk factors contribute to GI cancers, including age, gender, obesity, pathogenic infections, smoking cigarettes, alcohol consumption and dietary habits. Most of these cancers are sporadic. However, some patients are at high risk due to a family history of GI cancers. Systemic diseases affect multiple organs, and their chronic occurrence elicits inflammatory responses at various sites. These diseases also contribute to GI cancers.</p><p><strong>Conclusion and relevance: </strong>In this review, we discuss that untreated systemic diseases, including diabetes, hepatitis, acquired immune deficiency syndrome, ulcers and hypertension, can potentially lead to GI cancers if they remain untreated for a longer period. Systemic diseases initiate oxidative stress, inflammatory pathways and genetic manipulations, which altogether confer risks to GI cancers. Here, we describe the association between systemic diseases and their underlying mechanisms leading to GI cancers.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"9 2","pages":"473"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/20/88/JCAS-9-473.PMC10405983.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9988924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Large Bowel Perforation in Patients with Colorectal Cancer: A South African Perspective. 结直肠癌患者的大肠穿孔:南非的观点。
Pub Date : 2023-01-01 DOI: 10.37029/jcas.v9i1.517
Jocelynn Norman, Yoshan Moodley

Introduction: Large bowel perforation (LBP) occurs in up to 10% of colorectal cancer (CRC) patients and is a potential surgical emergency. Data on LBP in CRC patients from resource-limited countries are required to improve the management of this condition in these settings. Our study aimed to describe LBP amongst CRC patients in KwaZulu-Natal, South Africa.

Materials and methods: This was a descriptive sub-analysis of LBP data from an ongoing CRC registry. This study explores free and contained perforations and describes LBP characteristics, surgical management, histological findings, overall survival, and CRC recurrence.

Results: Ninety-four out of 2523 CRC patients had LBP (3.7%). The median age was 53.0 years (interquartile range: 43.0-64.0). The male-to-female ratio was 1.4:1. Thirty-three patients (35.1%) had a coexisting bowel obstruction. Tumor site perforations occurred in 87 patients (92.6%) and were mostly in the sigmoid colon (36.2%). Perforations were contained in 77 patients (81.9%). Eighty-nine patients (94.7%) underwent resection (elective resection: 76/89 patients, 85.4%). The post-operative inpatient mortality rate was 2.2%. Most patients had Stage III CRC (46 patients, 48.9%) and moderately differentiated tumors (77 patients, 81.9%). Overall survival at 12 months following CRC diagnosis was 55.4%. The early recurrence rate for CRC disease was 5.4%.

Conclusion: Tumor site perforations predominated, and most were contained. Patients were younger when compared with the international literature. We reaffirm that diastatic-free and contained perforations are two distinct clinical entities.

导读:大肠穿孔(LBP)发生在高达10%的结直肠癌(CRC)患者中,是一种潜在的外科急诊。需要来自资源有限国家的CRC患者腰痛数据,以改善这些国家对这种疾病的管理。我们的研究旨在描述南非夸祖鲁-纳塔尔省结直肠癌患者的腰痛。材料和方法:这是对正在进行的CRC登记处的LBP数据的描述性亚分析。本研究探讨游离穿孔和包含穿孔,并描述腰痛特征、手术处理、组织学发现、总生存率和结直肠癌复发。结果:2523例结直肠癌患者中有94例(3.7%)发生LBP。中位年龄为53.0岁(四分位数范围为43.0 ~ 64.0)。男女比例为1.4:1。33例(35.1%)合并肠梗阻。肿瘤部位穿孔87例(92.6%),以乙状结肠穿孔居多(36.2%)。穿孔77例(81.9%)。89例(94.7%)患者行手术切除(76/89例,85.4%)。术后住院死亡率为2.2%。大多数患者为III期CRC(46例,48.9%)和中分化肿瘤(77例,81.9%)。结直肠癌诊断后12个月的总生存率为55.4%。结直肠癌早期复发率为5.4%。结论:以肿瘤部位穿孔为主,且多数为包治性穿孔。与国际文献相比,患者更年轻。我们重申,无压迫穿孔和包含穿孔是两个不同的临床实体。
{"title":"Large Bowel Perforation in Patients with Colorectal Cancer: A South African Perspective.","authors":"Jocelynn Norman,&nbsp;Yoshan Moodley","doi":"10.37029/jcas.v9i1.517","DOIUrl":"https://doi.org/10.37029/jcas.v9i1.517","url":null,"abstract":"<p><strong>Introduction: </strong>Large bowel perforation (LBP) occurs in up to 10% of colorectal cancer (CRC) patients and is a potential surgical emergency. Data on LBP in CRC patients from resource-limited countries are required to improve the management of this condition in these settings. Our study aimed to describe LBP amongst CRC patients in KwaZulu-Natal, South Africa.</p><p><strong>Materials and methods: </strong>This was a descriptive sub-analysis of LBP data from an ongoing CRC registry. This study explores free and contained perforations and describes LBP characteristics, surgical management, histological findings, overall survival, and CRC recurrence.</p><p><strong>Results: </strong>Ninety-four out of 2523 CRC patients had LBP (3.7%). The median age was 53.0 years (interquartile range: 43.0-64.0). The male-to-female ratio was 1.4:1. Thirty-three patients (35.1%) had a coexisting bowel obstruction. Tumor site perforations occurred in 87 patients (92.6%) and were mostly in the sigmoid colon (36.2%). Perforations were contained in 77 patients (81.9%). Eighty-nine patients (94.7%) underwent resection (elective resection: 76/89 patients, 85.4%). The post-operative inpatient mortality rate was 2.2%. Most patients had Stage III CRC (46 patients, 48.9%) and moderately differentiated tumors (77 patients, 81.9%). Overall survival at 12 months following CRC diagnosis was 55.4%. The early recurrence rate for CRC disease was 5.4%.</p><p><strong>Conclusion: </strong>Tumor site perforations predominated, and most were contained. Patients were younger when compared with the international literature. We reaffirm that diastatic-free and contained perforations are two distinct clinical entities.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"9 1","pages":"517"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ee/62/JCAS-9-517.PMC10187599.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9541313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilisation Patterns and Treatment Outcomes of EGFR-Tyrosine Kinase Inhibitors in EGFR-mutant Advanced Lung Carcinoma in the Pakistani-Asian Population: A Real-world Data Study. egfr -酪氨酸激酶抑制剂在巴基斯坦-亚洲人群egfr突变晚期肺癌中的使用模式和治疗结果:一项真实世界数据研究
Pub Date : 2023-01-01 DOI: 10.37029/jcas.v9i1.491
Kiran Munawar, Romena Qazi, Hassan Shahryar Sheikh

Introduction: Data on the utilisation of epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) and their clinical outcomes in a heterogeneous Pakistani-Asian population have not been previously reported. This manuscript presents the first account of the clinical outcomes of EFGR-TKIs in EGFR-mutant lung adenocarcinoma among Pakistani-Asians.

Materials and methods: A real-world data study was conducted on all advanced lung cancer patients harbouring EGFR-mutations from the cancer registry of Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. We identified three different patterns of the use of EGFR-TKIs (Groups 1, 2 and 3) that reflect the ground realities of cancer care and delivery in Pakistan. We also noted a significant proportion of patients (Group 4) without access to EGFR TKIs. We compared the objective response rates (ORR), progression-free survival (PFS) and overall survival (OS) of each of the four groups and reported their toxicity profile.

Results: Within the limitations of a retrospective analysis, we saw differences in the frequency of EGFR mutations in this population. However, response rates and long-term outcomes of EGFR TKI therapy were comparable with the existing data. The overall use of EGFR TKIs led to a superior outcome in ORR, PFS and OS compared to chemotherapy alone; (77.8% vs. 50.0%, 16.3 vs. 10.7 months; P = 0.099; 85.6 vs. 25.9 months, respectively; P = 0.13).

Conclusion: Except for modest differences, EGFR-mutant advanced lung adenocarcinoma outcomes among Pakistani-Asians are comparable to those of other populations.

关于表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKIs)在巴基斯坦-亚洲异种人群中的应用及其临床结果的数据此前尚未报道。这篇论文首次报道了egfr突变肺腺癌患者中EFGR-TKIs的临床结果。材料和方法:对来自巴基斯坦拉合尔Shaukat Khanum纪念癌症医院和研究中心癌症登记处的所有携带egfr突变的晚期肺癌患者进行了一项真实数据研究。我们确定了EGFR-TKIs使用的三种不同模式(1、2和3组),反映了巴基斯坦癌症治疗和交付的基本现实。我们还注意到有很大比例的患者(第4组)无法获得EGFR TKIs。我们比较了四组的客观缓解率(ORR)、无进展生存期(PFS)和总生存期(OS),并报告了它们的毒性特征。结果:在回顾性分析的局限性内,我们看到了该人群中EGFR突变频率的差异。然而,EGFR TKI治疗的反应率和长期结果与现有数据相当。与单独化疗相比,EGFR TKIs的整体使用在ORR、PFS和OS方面具有更好的结果;77.8% vs. 50.0%, 16.3 vs. 10.7个月;P = 0.099;85.6个月vs. 25.9个月;P = 0.13)。结论:除了适度差异外,egfr突变的晚期肺腺癌在巴基斯坦亚裔人群中的预后与其他人群相当。
{"title":"Utilisation Patterns and Treatment Outcomes of EGFR-Tyrosine Kinase Inhibitors in EGFR-mutant Advanced Lung Carcinoma in the Pakistani-Asian Population: A Real-world Data Study.","authors":"Kiran Munawar,&nbsp;Romena Qazi,&nbsp;Hassan Shahryar Sheikh","doi":"10.37029/jcas.v9i1.491","DOIUrl":"https://doi.org/10.37029/jcas.v9i1.491","url":null,"abstract":"<p><strong>Introduction: </strong>Data on the utilisation of epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) and their clinical outcomes in a heterogeneous Pakistani-Asian population have not been previously reported. This manuscript presents the first account of the clinical outcomes of EFGR-TKIs in EGFR-mutant lung adenocarcinoma among Pakistani-Asians.</p><p><strong>Materials and methods: </strong>A real-world data study was conducted on all advanced lung cancer patients harbouring EGFR-mutations from the cancer registry of Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. We identified three different patterns of the use of EGFR-TKIs (Groups 1, 2 and 3) that reflect the ground realities of cancer care and delivery in Pakistan. We also noted a significant proportion of patients (Group 4) without access to EGFR TKIs. We compared the objective response rates (ORR), progression-free survival (PFS) and overall survival (OS) of each of the four groups and reported their toxicity profile.</p><p><strong>Results: </strong>Within the limitations of a retrospective analysis, we saw differences in the frequency of EGFR mutations in this population. However, response rates and long-term outcomes of EGFR TKI therapy were comparable with the existing data. The overall use of EGFR TKIs led to a superior outcome in ORR, PFS and OS compared to chemotherapy alone; (77.8% vs. 50.0%, 16.3 vs. 10.7 months; <i>P</i> = 0.099; 85.6 vs. 25.9 months, respectively; <i>P</i> = 0.13).</p><p><strong>Conclusion: </strong>Except for modest differences, EGFR-mutant advanced lung adenocarcinoma outcomes among Pakistani-Asians are comparable to those of other populations.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"9 1","pages":"491"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5a/81/JCAS-9-491.PMC10187601.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9541315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Standardised Uptake Value in Organ Confined Prostate Cancer in 68-Ga- Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography Scan and its Correlation with Prostate Specific Antigen Level and Gleason Score. 68-Ga前列腺特异性膜抗原正电子发射断层扫描-计算机断层扫描的标准化摄摄值及其与前列腺特异性抗原水平和Gleason评分的相关性
Pub Date : 2023-01-01 DOI: 10.37029/jcas.v9i2.519
Haider Ali, Syed Rashid-Ul-Amin, Abdul Hai

Introduction: A positron emission tomography (PET) scan and a computed tomography (CT) scan are an integral part of oncological imaging and other modalities such as magnetic resonance imaging, CT or bone scintigraphy have some limitations in staging the workup of prostate carcinoma. Combined with tissue-specific markers like prostate-specific membrane antigen (PSMA), positron emitter-based functional imaging results have improved. Our study aimed to determine the Standardised Uptake Value (SUVmax) in prostate adenocarcinoma that is confined to the organ in Ga-68-PSMA PET-CT scans and how it correlates with prostate-specific antigen (PSA) levels and Gleason score (GS).

Materials and methods: This cross-sectional study was conducted at Sindh Institute of Urology and Transplantation (SIUT), Karachi, and includes subjects referred for a Ga68-PSMA PET-CT scan from September 2017 to January 2022. Histopathologic-proven adenocarcinoma prostate patients with organ-confined disease and PSA levels obtained within 6 weeks before the PSMA-PET-CT scan were included in the study. PET-CT images were semi-quantitatively analysed by measuring SUVmax and the result was interpreted using statistical software SPSS version 22.0.

Results: A total of 154 patients were analysed. The mean age of patients was 66.57 ± 8.86 years. The GS of all patients ranges from 6 to 10. The mean and median PSA levels were 32.33 ng/mL (range: 0.004-306.00) and 14.20 ng/mL, respectively. The mean SUVmax of all prostatic lesions was 14.67 ± 12.58 and the median value was 10.76. SUVmax was higher in patients with a PSA level of more than ten than those with a <10. The correlation of SUVmax with PSA and GS showed a significant correlation.

Conclusion: The SUVmax of organ-confined prostate cancer correlates well with PSA level and GS Median SUVmax and PSA directly relate to GS.

导读:正电子发射断层扫描(PET)和计算机断层扫描(CT)是肿瘤成像不可分割的一部分,而磁共振成像、CT或骨显像等其他方式在前列腺癌的分期方面有一定的局限性。结合组织特异性标志物如前列腺特异性膜抗原(PSMA),基于正电子发射器的功能成像结果得到改善。我们的研究旨在确定Ga-68-PSMA PET-CT扫描中局限于器官的前列腺腺癌的标准化摄取值(SUVmax)及其与前列腺特异性抗原(PSA)水平和Gleason评分(GS)的相关性。材料和方法:本横断面研究在卡拉奇Sindh泌尿外科和移植研究所(SIUT)进行,包括2017年9月至2022年1月期间进行Ga68-PSMA PET-CT扫描的受试者。组织病理学证实的伴有器官局限性疾病的前列腺腺癌患者和PSMA-PET-CT扫描前6周内获得的PSA水平被纳入研究。通过测量SUVmax对PET-CT图像进行半定量分析,并使用SPSS 22.0版统计软件对结果进行解释。结果:共分析了154例患者。患者平均年龄66.57±8.86岁。所有患者的GS值在6 ~ 10之间。PSA的平均值和中位数分别为32.33 ng/mL(范围:0.004-306.00)和14.20 ng/mL。所有前列腺病变的平均SUVmax为14.67±12.58,中位值为10.76。结论:器官局限性前列腺癌的SUVmax与PSA水平和GS有良好的相关性,SUVmax中值和PSA与GS有直接关系。
{"title":"Standardised Uptake Value in Organ Confined Prostate Cancer in 68-Ga- Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography Scan and its Correlation with Prostate Specific Antigen Level and Gleason Score.","authors":"Haider Ali,&nbsp;Syed Rashid-Ul-Amin,&nbsp;Abdul Hai","doi":"10.37029/jcas.v9i2.519","DOIUrl":"https://doi.org/10.37029/jcas.v9i2.519","url":null,"abstract":"<p><strong>Introduction: </strong>A positron emission tomography (PET) scan and a computed tomography (CT) scan are an integral part of oncological imaging and other modalities such as magnetic resonance imaging, CT or bone scintigraphy have some limitations in staging the workup of prostate carcinoma. Combined with tissue-specific markers like prostate-specific membrane antigen (PSMA), positron emitter-based functional imaging results have improved. Our study aimed to determine the Standardised Uptake Value (SUVmax) in prostate adenocarcinoma that is confined to the organ in Ga-68-PSMA PET-CT scans and how it correlates with prostate-specific antigen (PSA) levels and Gleason score (GS).</p><p><strong>Materials and methods: </strong>This cross-sectional study was conducted at Sindh Institute of Urology and Transplantation (SIUT), Karachi, and includes subjects referred for a Ga68-PSMA PET-CT scan from September 2017 to January 2022. Histopathologic-proven adenocarcinoma prostate patients with organ-confined disease and PSA levels obtained within 6 weeks before the PSMA-PET-CT scan were included in the study. PET-CT images were semi-quantitatively analysed by measuring SUVmax and the result was interpreted using statistical software SPSS version 22.0.</p><p><strong>Results: </strong>A total of 154 patients were analysed. The mean age of patients was 66.57 ± 8.86 years. The GS of all patients ranges from 6 to 10. The mean and median PSA levels were 32.33 ng/mL (range: 0.004-306.00) and 14.20 ng/mL, respectively. The mean SUVmax of all prostatic lesions was 14.67 ± 12.58 and the median value was 10.76. SUVmax was higher in patients with a PSA level of more than ten than those with a <10. The correlation of SUVmax with PSA and GS showed a significant correlation.</p><p><strong>Conclusion: </strong>The SUVmax of organ-confined prostate cancer correlates well with PSA level and GS Median SUVmax and PSA directly relate to GS.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"9 2","pages":"529"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/81/93/JCAS-9-519.PMC10405982.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9988921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Case Report on Rare Case of Pancreatic Metastasis from Primary Lung Adenocarcinoma: Treated Through a Non-surgical Approach. 罕见的原发性肺腺癌胰腺转移病例报告:通过非手术方法治疗。
Pub Date : 2023-01-01 DOI: 10.37029/jcas.v9i2.507
Syed Mohsin Raza, Adeel Riaz, Aqueel Shahid, Tabinda Sadaf

Introduction: Most frequent sites of metastasis from lung cancer are the liver, brain and adrenal. Pancreas is an infrequent site of solitary metastasis from the lung primary with limited treatment options. There is insufficient data on the prognosis and optimal management of such cases.

Case description: We report a case of 44-year-old gentleman diagnosed with locally advanced lung adenocarcinoma Stage T4N3 who was treated radically with chemoradiation therapy, followed by a relapse of solitary pancreatic metastasis, which was treated with targeted therapy, erlotinib, due to the presence of epidermal growth factor receptor (EGFR) mutation.

Practical implications: This case reports an excellent radiological and symptomatic response in a patient who received erlotinib for advanced non-small-cell lung cancer (NSCLC). The use of EGFR-tyrosine kinase inhibitors has led to better prognosis and longer progression-free survival for patients with advanced NSCLC. However, the long-term survival of patients with metastatic NSCLC is limited.

简介:肺癌最常见的转移部位是肝、脑和肾上腺。胰腺是肺原发灶孤立转移的少见部位,治疗选择有限。关于此类病例的预后和最佳处理的数据不足。病例描述:我们报告了一例44岁的男性,被诊断为局部晚期肺腺癌T4N3期,他接受了放化疗的彻底治疗,随后孤立性胰腺转移复发,由于表皮生长因子受体(EGFR)突变的存在,他接受了靶向治疗厄洛替尼的治疗。实际意义:本病例报告了一名接受厄洛替尼治疗晚期非小细胞肺癌(NSCLC)的患者的出色放射学和症状反应。egfr -酪氨酸激酶抑制剂的使用为晚期NSCLC患者带来了更好的预后和更长的无进展生存期。然而,转移性NSCLC患者的长期生存是有限的。
{"title":"A Case Report on Rare Case of Pancreatic Metastasis from Primary Lung Adenocarcinoma: Treated Through a Non-surgical Approach.","authors":"Syed Mohsin Raza,&nbsp;Adeel Riaz,&nbsp;Aqueel Shahid,&nbsp;Tabinda Sadaf","doi":"10.37029/jcas.v9i2.507","DOIUrl":"https://doi.org/10.37029/jcas.v9i2.507","url":null,"abstract":"<p><strong>Introduction: </strong>Most frequent sites of metastasis from lung cancer are the liver, brain and adrenal. Pancreas is an infrequent site of solitary metastasis from the lung primary with limited treatment options. There is insufficient data on the prognosis and optimal management of such cases.</p><p><strong>Case description: </strong>We report a case of 44-year-old gentleman diagnosed with locally advanced lung adenocarcinoma Stage T4N3 who was treated radically with chemoradiation therapy, followed by a relapse of solitary pancreatic metastasis, which was treated with targeted therapy, erlotinib, due to the presence of epidermal growth factor receptor (EGFR) mutation.</p><p><strong>Practical implications: </strong>This case reports an excellent radiological and symptomatic response in a patient who received erlotinib for advanced non-small-cell lung cancer (NSCLC). The use of EGFR-tyrosine kinase inhibitors has led to better prognosis and longer progression-free survival for patients with advanced NSCLC. However, the long-term survival of patients with metastatic NSCLC is limited.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"9 2","pages":"507"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/38/e7/JCAS-9-507.PMC10405981.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9995289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of cancer & allied specialties
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1